Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
12.39
+1.86 (17.66%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
12.23
-0.16 (-1.33%)
Bozordan keyin: Jun 26, 2026, 7:59 PM EDT
SELLAS Life Sciences Group, Inc., kechki bosqichdagi klinik biofarmatsevtika kompaniyasi bo'lib, Qo'shma Shtatlarda turli xil rak ko'rsatkichlari uchun yangi davolash usullarini ishlab chiqishga qaratilgan. Kompaniyaning yetakchi mahsuloti nomzodi galinpepimut-S (GPS) bo'lib, u Wilms tumor 1, antigeniga qarshi yo'naltirilgan peptid immunoterapiyasi; va SLS009 (tambiciclib) bo'lib, u tanlab kichik molekulali siklin-bog'liq kinaza 9, yoki CDK9 ingibitoridir. Kompaniya Merck & Co., Inc. bilan GPS ni PD1 blokatori pembrolizumab bilan birgalikda 1/2 faza klinik sinovida baholash bo'yicha strategik hamkorlikka ega, unda beshta rak ko'rsatkichlari, shu jumladan gematologik malignliklar va qattiq o'smalari bo'lgan bemorlar qatnashadi; GFH009 ni ishlab chiqish va tijoratlashtirish uchun GenFleet Therapeutics (Shanghai), Inc.; va MSK ning WT1 peptidli vaktsina texnologiyasini ishlab chiqish va tijoratlashtirish uchun Memorial Sloan Kettering Cancer Center. SELLAS Life Sciences Group, Inc. Nyu-York, Nyu-Yorkda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Angelos M. Stergiou M.D., ScD h.c. | Founder, President, CEO & Director |
| Dr. Dragan Cicic M.D., MBA | Senior VP & Chief Development Officer |
| Mr. Andrew Elnatan | Senior VP of Regulatory Affairs, CMC & Quality |
| Mr. John Thomas Burns CPA | Senior VP & CFO |
| Ms. Stacy E. Yeung | VP, General Counsel & Corporate Secretary |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-25 | 8-K | tm2618927d1_8k.htm |
| 2026-06-18 | 8-K | tm2618311d1_8k.htm |
| 2026-06-16 | S-8 | tm2617870d1_s8.htm |
| 2026-06-02 | 8-K | tm2616601d1_8k.htm |
| 2026-05-12 | 8-K | sls-20260512.htm |
| 2026-05-12 | 10-Q | sls-20260331.htm |
| 2026-04-23 | DEFA14A | tm261477d3_defa14a.htm |
| 2026-04-23 | DEF 14A | tm261477-1_def14a.htm |
| 2026-04-23 | ARS | tm2612539d1_ars.pdf |
| 2026-03-20 | S-3ASR | tm269045d1_s3asr.htm |